DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes
Patients with <i>BRCA1/2</i>-mutated PC had significantly improved outcomes to PARPi but not platinum chemotherapy compared with those with HRR mutations without direct BRCA complex interaction.
Authors
- Matthew Labriola (ORCID: https://orcid.org/0000-0003-0919-9864)
- Michael Thomas Schweizer (ORCID: https://orcid.org/0000-0002-5510-0661)
- Laura Graham (ORCID: https://orcid.org/0000-0003-4371-572X)
- Olesia Kellezi
- Vadim S. Koshkin (ORCID: https://orcid.org/0000-0003-2277-8668)
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Ajjai Alva (ORCID: https://orcid.org/0000-0002-1898-3522)
- Clara Hwang (ORCID: https://orcid.org/0000-0002-0998-323X)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Rohan Garje (ORCID: https://orcid.org/0000-0002-7244-5602)
- Pedro Coelho Barata (ORCID: https://orcid.org/0000-0002-8890-2951)
- Deepak Kilari (ORCID: https://orcid.org/0000-0002-6999-1901)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- George Mo (ORCID: https://orcid.org/0009-0009-0677-3147)
- Vaibhav G. Patel (ORCID: https://orcid.org/0000-0003-2004-7298)
- Shoshana Rothstein
- Abhishek Tripathi (ORCID: https://orcid.org/0000-0002-5198-0673)
- Michael Pierro (ORCID: https://orcid.org/0000-0003-1047-7614)
- Bicky Thapa (ORCID: https://orcid.org/0000-0002-7636-8907)
- Tanya Barauskas Dorff (ORCID: https://orcid.org/0000-0001-5990-298X)
- Joseph J. Park (ORCID: https://orcid.org/0000-0003-1311-5416)
- Nicholas Henderson (ORCID: https://orcid.org/0000-0003-3184-0945)
Institutions
- Baptist Hospital of Miami (US)
- Emory University (US)
- University of California, San Francisco (US)
- Wayne State University (US)
- University of Washington (US)
- Medical College of Wisconsin (US)
- University of Michigan (US)
- Henry Ford Hospital (US)
- University of California San Diego (US)
- Fred Hutch Cancer Center (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Baptist Health South Florida (US)
- City of Hope (US)
- University Hospitals Seidman Cancer Center (US)
- Duke Medical Center (US)
- Oklahoma State University Oklahoma City (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- OU Health Stephenson Cancer Center
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/po.24.00014
- Citations
- 7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Genomic Health
- Endocyte
- Exelixis
- Incyte
- Calithera Biosciences
- Seagen
- Eisai
- Astellas Pharma
- Genentech
- EMD Serono